Tactile Systems Technology, Inc.

TCMD

$22.06

+0.23%

2026-09-04 12:11:38 EDT+$0.05

Healthcare

Medical - Devices

NASDAQ

Active Trading

Tactile Systems Technology, Inc. is a medical technology firm that develops and supplies specialized devices to treat chronic health conditions across the ...

Price Action of TCMD

$22.06

+0.23%+$0.05

High—

Low—

52W High-41.6%

Rel. vol—

Interval

Range2.5h

Volume—SMA5SMA10

—

Tactile Systems Technology, Inc. (Nasdaq: TCMD), known as Tactile Medical, is a Minneapolis-based medical technology firm founded in 1995. The company specializes in developing and commercializing at-home therapeutic devices for chronic conditions, with a focus on improving quality of life and reducing healthcare costs. Its core product lines include: Flexitouch ...Tactile Systems Technology, Inc. (Nasdaq: TCMD), known as Tactile Medical, is a Minneapolis-based medical technology firm founded in 1995. The company specializes in developing and commercializing at-home therapeutic devices for chronic conditions, with a focus on improving quality of life and reducing healthcare costs. Its core product lines include: Flexitouch Plus, an advanced pneumatic compression device for lymphedema and venous disorders; Entre, a portable system for at-home treatment of chronic venous insufficiency and venous ulcers; and AffloVest, a high-frequency chest wall oscillation vest for airway clearance in conditions like cystic fibrosis and bronchiectasis. With over 1,086 employees, the company serves the US healthcare market through direct sales and payer reimbursement support. Financially, Tactile Medical reported revenue of approximately $329.5 million in 2024, with a market cap around $665 million. The company emphasizes innovation, evidenced by R&D investment (2.8% of revenue) and a pipeline of new products. Leadership includes CEO Sheri Dodd, who brings 30 years of healthcare experience, aiming to drive growth and operational efficiency. Tactile Medical's integrated care approach includes patient education and remote monitoring, contributing to its gross profit margin of 75.7%. The company is committed to expanding its platform and addressing unmet needs in chronic care.ExpandCollapse

Founded

1995

Employees

1086

CEO

Sheri Louise Dodd

Full Name

Tactile Systems Technology, Inc.

Sector

Healthcare

Industry

Medical - Devices

ROE

11.49%

Market Cap

$0.50B

Current Ratio

4.12

WACC

8.34%

ROIC

11.22%

Contact Information

https://www.tactilemedical.com

612 355 5100

3701 Wayzata Boulevard, Minneapolis, MN 55416

Key Metrics of TCMD

Snapshot

Latest / TTM · 6 periods

Market Cap

$499.71M

ROCE

14.5%

EV / EBITDA

9.99x

+1.9% YoY

FCF Yield

5.4%

-0.7% YoY

Cash Conversion Cycle

81.0d

Current Ratio

4.12

Quick take

TTM —

Positive CCC

Financial Highlights of TCMD

Profitability trend

Latest / TTM · 6 periods

Gross Margin

74.2%

Net Margin

7.1%

P/E Ratio

20.19x

n/a

Debt / Equity

0.06

n/a

Current Ratio

4.12

Dividend Yield

0.0%

Understanding

TTM —

No major balance sheet stress in these headline ratios.

Calendar of TCMD

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $0.28 · Revenue $92.00M · 2 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $0.57 · Revenue $109.44M · 2 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $1.12 · Revenue $362.38M · 2 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.00 · Revenue $81.92M · 1 analysts

Recent history

Aug 10, 2026
Q2 FY2026 · Results reported
EPS $0.34 · Revenue $85.70M
View filing
May 4, 2026
Q1 FY2026 · Results reported
EPS $-0.08 · Revenue $75.27M
View filing
Feb 17, 2026
FY2025 · Annual results
EPS $0.82 · Revenue $329.52M
View filing
Nov 3, 2025
Q3 FY2025 · Results reported
EPS $0.36 · Revenue $85.75M
View filing
Aug 4, 2025
Q2 FY2025 · Results reported
EPS $0.14 · Revenue $78.91M
View filing
May 5, 2025
Q1 FY2025 · Results reported
EPS $-0.13 · Revenue $61.27M
View filing

Financial Statements of TCMD

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$329.5M	+12.5%	+13.9%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$19.1M	+12.5%	+541.6%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+75.2%	+1.6%	-10.3%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+8.9%	+17.4%	+490.8%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+5.8%	+0.1%	+487.8%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$40.4M	+6.0%	+269.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+12.3%	-5.8%	+248.6%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	7.3%	-65.0%	-7.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	4.03x	-7.6%	-2.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$273.9M	-8.0%	+2.8%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	0.82 vs 0.80	+3.0%	0.34 vs 0.28	+22.9%
Revenue Surprise	$329.5M vs $319.7M	+3.1%	$85.7M vs $92.0M	-6.9%

Insider Transactions of TCMD

Acquisitions (A)

Since May 6, 2026

Disposals (D)

Since May 6, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 10, 2026	Dodd Sheri Louise	director, officer: Chief Executive Officer	Common Stock	D	10,978	$29.44
May 11, 2026	Birkemeyer Elaine M.	officer: CHIEF FINANCIAL OFFICER	Common Stock	D	4,631	$24.49
May 6, 2026	Asbury Valerie L.	director	Common Stock	A	6,521	—
May 6, 2026	Huggenberger Raymond	director	Common Stock	A	6,521	—
May 6, 2026	King Laura G.	director	Common Stock	A	6,521	—

Earnings Call Transcript of TCMD

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Welcome, ladies and gentlemen, to the second quarter 2026 Earnings Conference Call for Tactile Medical. [Operator Instructions] Please note that this conference call is being recorded and will be available on the company's website for replay shortly. I would now like to turn the call over to Sam Bentzinger, Investor Relations at Gilmartin Group, for a few introductory comments. Please go ahead. Sam Bentzinger: Good afternoon and thank you for joining today's call. With me from Tactile's management team are Sheri Dodd, Chief Executive Officer, and Elaine Birkemeyer, Chief Financial Officer. Before we begin, I'd like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and are not intended to be used to address the problems of the current inherent risks, and uncertainties. These could cause actual results to differ materially from those indicated, including those identified in the risk factor section of our annual report on Form 10-K, as well as our most recent 10-Q filing to be filed with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events, or otherwise. This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investors Relations portion of our website. With that, I'll now turn the call over to Sheri. Sheri Dodd: Thanks, Sam. Good afternoon, everyone, and welcome to our Second Quarter 2026 Earnings Call. Here with me is Elaine Birkemeyer, our Chief Financial Officer. We delivered another strong quarter of execution in Q2, highlighted by continued strength in our lymphedema business and meaningful profitability expansion. Total revenue was $85.7 million, up 9% year-over-year, with lymphedema contributing $73.6 million, up 12% year-over-year. AffloVest contributed $12.1 million, a 7% decline year-over-year due to temporary inventory management dynamics among several of our large DME partners associated with the launch of our next-generation AffloVest system during the quarter. Importantly, on a trailing 12-month basis, AffloVest revenue remains up 32% year-over-year, underscoring the durability of the underlining growth trend, even as we work through this near-term dynamic, which I will touch on shortly. Our strong revenue performance was complemented by another quarter of meaningful profitability expansion. Gross margin improved 180 basis points …

Leadership Team of TCMD

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Sheri Louise Dodd	Chief Executive Officer, President & Director	USD 1,446,938	Female	1966	Active
Elaine Birkemeyer	Chief Financial Officer	USD 778,000	Female	1975	Active
Kristie T. Burns	Senior Vice President of Business Development	USD 647,500	Female	1972	Active
Aaron R. Snodgrass	Senior Vice President of Sales	USD 431,996	—	—	Active
John David Kaercher	Chief Information Officer	—	Male	—	Active
Janelle Strop	Chief Human Resource Officer	—	—	—	Active
Antonios Gasparis	Chief Medical Officer & Member of Vascular Strategic Advisory Board	—	—	—	Active
Nicolaus Wilson	Senior Vice President of Marketing & Market Access	—	Male	—	Active
Jerry A. Sauber	Senior Vice President of Manufacturing, Operations, R&D	—	Male	—	Active
Sunday J. Hoy	Vice President of Regulatory Affairs & Chief Compliance Officer	—	Female	—	Active

Recent News of TCMD

Seeking Alpha8/10/2026Neutral

Tactile Systems Technology, Inc. (TCMD) Q2 2026 Earnings Call Transcript

MarketBeat8/10/2026Neutral

Tactile Systems Technology Q2 Earnings Call Highlights

Tactile Systems Technology NASDAQ: TCMD, doing business as Tactile Medical, reported second-quarter revenue growth and higher profitability, led by its lymphedema business, while updating its full-year outlook to reflect temporary inventory effects in its airway-clearance segment.

Zacks Investment Research8/10/2026Neutral

Tactile Systems Technology (TCMD) Beats Q2 Earnings and Revenue Estimates

Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.14 per share a year ago.

GlobeNewsWire7/21/2026Neutral

Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026

MINNEAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2026 financial results will be released after the market closes on Monday, August 10, 2026.

GlobeNewsWire7/13/2026Neutral

Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

Discreet, Battery-Powered Device Reaches Patients at Earlier Stages of Disease Progression Discreet, Battery-Powered Device Reaches Patients at Earlier Stages of Disease Progression

Historical Employee Count of TCMD

Current

1,086

Change

+4.73%

Minimum

982

Maximum

1,086

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	1,086	10-K	Feb 17, 2026	View
Dec 31, 2024	1,037	10-K	Feb 18, 2025	View
Dec 31, 2023	992	10-K	Feb 20, 2024	View
Dec 31, 2022	982	10-K	Feb 21, 2023	View
Dec 31, 2021	988	10-K	Feb 23, 2022	View

Related stocksMedical - Devices

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Tactile Systems Technology, Inc.